I
Imagen Biotech
Imagen Biotech - Vision in Sight
About Imagen Biotech
Imagen Biotech, operating as Imagen Therapeutics, is a contract research organization focused on accelerating oncological drug discovery and development. Founded in 2007 by former AstraZeneca cell biologists Geoff Muckle and Gareth Griffiths, the company leverages its specialized platform to support the cancer research community. Geoff Muckle, the CEO, brings two decades of experience in pharmaceuticals, with a background in commercial and management roles at major companies like GSK, Bayer, and Roche before transitioning into contract research and leading Imagen. The firm's primary offering is a diagnostic tool that assists oncologists in selecting appropriate treatments for patients, thereby improving outcomes.
The company's business model is centered on providing contract research services to biopharma companies. Its platform is designed to expedite the discovery and development programs of its clients. Operating from Manchester and Sci-Tech Daresbury in the UK, Imagen Therapeutics provides a flexible and proficient High Content Screening service, positioning itself as a dedicated High Content Biology company. This service helps scientists enhance their research efficiency and output. The company's work supports the broader trend in medicine towards personalized treatments, which is driving growth in the organoid and 3D cell culture market. This market, essential for more accurate preclinical drug screening, is projected to expand significantly, with some forecasts predicting it will reach over USD 11 billion by 2033.
Imagen Therapeutics' growth trajectory included a move to a new base in the Liverpool city region, backed by a grant from the Liverpool City Region Combined Authority’s Inward Investment Facilitation Fund, with plans to significantly expand its workforce. The company, which was formerly known as Imagen Biotech, has raised a total of $19.8 million in funding to support its operations and expansion efforts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- New York City, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 57.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Visualization, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2011 | $40M | $160M | SV Health Investors · Novo Ventures · F-Prime | — |
Growth signals
Latest recorded traffic for Imagen Biotech is 140 monthly website visits. Imagen Biotech's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Imagen Biotech in the New York City ecosystem
The Imagen Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
SV Health Investors
Novo Ventures
F-Prime
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Imagen Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Imagen Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







